The DOI matches its Crossref record; 182 of the 182 references it cites were found in a registry or an index.
Nanoparticles for Brain Drug Delivery
Open accessAbstract
The central nervous system, one of the most delicate microenvironments of the body, is protected by the blood-brain barrier (BBB) regulating its homeostasis. BBB is a highly complex structure that tightly regulates the movement of ions of a limited number of small molecules and of an even more restricted number of macromolecules from the blood to the brain, protecting it from injuries and diseases. However, the BBB also significantly precludes the delivery of drugs to the brain, thus, preventing the therapy of a number of neurological disorders. As a consequence, several strategies are currently being sought after to enhance the delivery of drugs across the BBB. Within this review, the recently born strategy of brain drug delivery based on the use of nanoparticles, multifunctional drug delivery systems with size in the order of one-billionth of meters, is described. The review also includes a brief description of the structural and physiological features of the barrier and of the most utilized nanoparticles for medical use. Finally, the potential neurotoxicity of nanoparticles is discussed, and future technological approaches are described. The strong efforts to allow the translation from preclinical to concrete clinical applications are worth the economic investments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Colowick, S. P., Joshi, M. D., Jagannathan, & KAPLAN, N. O. (1966) · Cited by 26,137
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,827
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864
Translocation of inhaled ultrafine particles to the brain
Oberdörster, G., Sharp, Z., Atudorei, V., Elder, A., Gelein, R., Kreyling, W., & Cox, C. (2004) · Inhalation Toxicology · doi:10.1080/08958370490439597 · Cited by 2,606
Drug Transport across the Blood–Brain Barrier
Pardridge, W. M. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.126 · Cited by 1,994
Diffusion in Brain Extracellular Space
Syková, E., & Nicholson, C. (2008) · Physiological Reviews · doi:10.1152/physrev.00027.2007 · Cited by 1,481
Drug Development and Industrial Pharmacy
Rhodes, C. T. (1995) · Drug Development and Industrial Pharmacy · doi:10.3109/03639049509070870 · Cited by 1,263
Translocation of Inhaled Ultrafine Manganese Oxide Particles to the CentralNervous System
Elder, A., Gelein, R., Silva, V., Feikert, T., Opanashuk, L., Carter, J., Potter, R., Maynard, A., Ito, Y., Finkelstein, J., et al. (2006) · Environmental Health Perspectives · doi:10.1289/ehp.9030 · Cited by 1,180
Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Parodi, A., Quattrocchi, N., van de Ven, A. L., Chiappini, C., Evangelopoulos, M., Martinez, J. O., Brown, B. S., Khaled, S. Z., Yazdi, I. K., Enzo, M. V., et al. (2013) · Nature Nanotechnology · doi:10.1038/nnano.2012.212 · Cited by 1,168
Cited by
Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
“Very often it also accelerates blood clearance of theNPs through the reticuloendothelial system localized mostly in the spleen and liver [39,68], which may decrease the NP dose available for accumulation in the brain aswell as induce inflammation.”
BackgroundTherapeutic efficacy of nanoparticles and routes of administration
Chenthamara, D., Subramaniam, S., Ramakrishnan, S. G., Krishnaswamy, S., Essa, M. M., Lin, F.-H., & Qoronfleh, M. W. (2019) · Biomaterials Research · doi:10.1186/s40824-019-0166-x · Cited by 1,055
Current Strategies for Brain Drug Delivery
Dong, X. (2018) · Theranostics · doi:10.7150/thno.21254 · Cited by 954
“However, some studies suggested that nanoparticles may not be internalized by cells and the enhanced drug uptake in the brain is non-specific [29, 42, 43].”
BackgroundOvercoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Tapeinos, C., Battaglini, M., & Ciofani, G. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.033 · Cited by 539
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Ahn, S. I., Sei, Y. J., Park, H.-J., Kim, J., Ryu, Y., Choi, J. J., Sung, H.-J., MacDonald, T. J., Levey, A. I., & Kim, Y. (2020) · Nature Communications · doi:10.1038/s41467-019-13896-7 · Cited by 402
Role of the Blood–Brain Barrier in Multiple Sclerosis
Ortiz, G. G., Pacheco-Moisés, F. P., Macías-Islas, M. Á., Flores-Alvarado, L. J., Mireles-Ramírez, M. A., González-Renovato, E. D., Hernández-Navarro, V. E., Sánchez-López, A. L., & Alatorre-Jiménez, M. A. (2014) · Archives of Medical Research · doi:10.1016/j.arcmed.2014.11.013 · Cited by 373
Applications of nanotechnology in drug delivery to the central nervous system
Saeedi, M., Eslamifar, M., Khezri, K., & Dizaj, S. M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.133 · Cited by 342
Loureiro, J., Andrade, S., Duarte, A., Neves, A., Queiroz, J., Nunes, C., Sevin, E., Fenart, L., Gosselet, F., Coelho, M., et al. (2017) · Molecules · doi:10.3390/molecules22020277 · Cited by 341
Strategies for transporting nanoparticles across the blood–brain barrier
Zhang, T.-T., Li, W., Meng, G., Wang, P., & Liao, W. (2016) · Biomaterials Science · doi:10.1039/c5bm00383k · Cited by 308
Nanotechnology-based drug delivery systems for the treatment of Alzheimer’s disease
Fonseca-Santos, B., Chorilli, M., & Palmira Daflon Gremião, M. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s87148 · Cited by 308
Nano carriers for drug transport across the blood–brain barrier
Li, X., Tsibouklis, J., Weng, T., Zhang, B., Yin, G., Feng, G., Cui, Y., Savina, I. N., Mikhalovska, L. I., Sandeman, S. R., et al. (2017) · Journal of Drug Targeting · doi:10.1080/1061186x.2016.1184272 · Cited by 282
Nanomaterial based drug delivery systems for the treatment of neurodegenerative diseases
Masoudi Asil, S., Ahlawat, J., Guillama Barroso, G., & Narayan, M. (2020) · Biomaterials Science · doi:10.1039/d0bm00809e · Cited by 181
Resveratrol Brain Delivery for Neurological Disorders Prevention and Treatment
Andrade, S., Ramalho, M. J., Pereira, M. D. C., & Loureiro, J. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01261 · Cited by 173
Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery
Aday, S., Cecchelli, R., Hallier-Vanuxeem, D., Dehouck, M. P., & Ferreira, L. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.01.001 · Cited by 169
Liver Dysfunction as a Novel Player in Alzheimer’s Progression: Looking Outside the Brain
Estrada, L. D., Ahumada, P., Cabrera, D., & Arab, J. P. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00174 · Cited by 144
Cano, A., Sánchez-López, E., Ettcheto, M., López-Machado, A., Espina, M., Souto, E. B., Galindo, R., Camins, A., García, M. L., & Turowski, P. (2020) · Nanomedicine · doi:10.2217/nnm-2019-0443 · Cited by 144
Nose-To-Brain Delivery of PLGA-Diazepam Nanoparticles
Sharma, D., Sharma, R. K., Sharma, N., Gabrani, R., Sharma, S. K., Ali, J., & Dang, S. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-015-0294-0 · Cited by 127
Rabanel, J.-M., Piec, P.-A., Landri, S., Patten, S. A., & Ramassamy, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.042 · Cited by 102
Nanotechnology to improve the Alzheimer’s disease therapy with natural compounds
Ramalho, M. J., Andrade, S., Loureiro, J. A., & do Carmo Pereira, M. (2020) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00694-3 · Cited by 75
Rhaman, M. M., Islam, M. R., Akash, S., Mim, M., Noor alam, M., Nepovimova, E., Valis, M., Kuca, K., & Sharma, R. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.989471 · Cited by 63
“The BBB changes could affect the dosing, effectiveness, and adverse effects of regularly utilized medications in general (Masserini, 2013).”
BackgroundInfluentialAlzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Iqbal, I., Saqib, F., Mubarak, Z., Latif, M. F., Wahid, M., Nasir, B., Shahzad, H., Sharifi-Rad, J., & Mubarak, M. S. (2024) · European Journal of Medical Research · doi:10.1186/s40001-024-01915-3 · Cited by 60
Prabhu, S., Goda, J. S., Mutalik, S., Mohanty, B. S., Chaudhari, P., Rai, S., Udupa, N., & Rao, B. S. S. (2017) · Nanoscale · doi:10.1039/c7nr00305f · Cited by 54
Metadata
- Authors
- Masserini, M.
- Venue
- ISRN Biochemistry
- Publisher
- Hindawi Limited
- Published
- 2013-05-21
- Volume
- 2013
- Pages
- 1-18
- ISSN
- 2090-7729 (ISSN-L)
- OpenAlex
- W2011005493
- Cited by
- 489
- References
- 182
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.